Commissioning and Qualification the ASTM E2500 Way: Verification, SMEs, and the Science-Based Approach

For two decades, qualifying manufacturing equipment meant running a fixed liturgy: Installation Qualification, Operational Qualification, Performance Qualification. Each had its protocol, its dry-run, its line-by-line execution, its signature blocks. The trouble was that the liturgy was applied uniformly. A non-product-contact compressed-air dryer got the same protocol weight as a sterilizer. Vendor test data that was perfectly good got re-executed at the site because “we always do IQ.” The result was a lot of paper, a lot of cost, and not necessarily a lot of assurance about the things that actually affect the product.

ASTM E2500 is the standard that put a different idea on paper: spend your qualification effort where the risk to product quality and patient safety lives, verify rather than blindly re-test, and let people who actually understand the system (the subject matter experts) make the acceptance decisions. This article covers what the standard says, how a verification program is built and run, how it interacts with IQ/OQ/PQ language that has not gone away, and how to defend it in front of an inspector.

What ASTM E2500 actually is

The full title is ASTM E2500, “Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment.” It was first issued in 2007 and has been revised since. The current revision is ASTM E2500-25, published 15 March 2025 (its title adds the subtitle “Science and Risk Based Approach”), which superseded E2500-20 (2020) and the earlier E2500-13 and E2500-07. It is a consensus standard published by ASTM International, not a regulation. No regulator wrote it and no regulator mandates it. You will not find “thou shalt use E2500” in any CFR part or EU directive.

That matters for how you talk about it. E2500 is an acceptable approach to meeting GMP expectations, not an obligation. It is widely recognized because its principles line up with what regulators already ask for: a lifecycle approach, risk management, and a focus on critical quality attributes.

The companion document most teams actually work from is the ISPE Baseline Guide Volume 5, Commissioning and Qualification (Second Edition, 2019). ISPE wrote the original Baseline Guide that seeded E2500 thinking, then rewrote Volume 5 to align with E2500 and with ICH Q8/Q9/Q10. When practitioners say “we run a C&Q program,” they usually mean an E2500-aligned, ISPE Baseline Guide Volume 5 (Second Edition) program. The two are meant to be used together: E2500 gives the principles, the Baseline Guide gives the how.

The five principles

E2500 is built on a small set of ideas. Know them cold, because interviewers ask for them by name.

1. Risk-based approach. Apply effort proportional to risk to product quality and patient safety. Quality risk management per ICH Q9 drives scope.
2. Science-based approach. Decisions rest on process and product understanding (the design space, the critical quality attributes, the critical process parameters), not on habit.
3. Critical aspects. Work out which parts of the system genuinely bear on whether the product comes out right and whether the patient is safe. In practice that means going through the design element by element and asking which controls, measurements, materials of construction, and behaviours the process actually depends on to hold quality where it needs to be. Those are the ones that get verified against predefined acceptance criteria. Everything else is delivered under good engineering practice and carries no GMP verification burden.
4. Quality by design and good engineering practice. Quality is built in during specification and design, not inspected in at the end. Good engineering practice (GEP) underpins the whole lifecycle.
5. Subject matter expert decisions. SMEs, not QA alone, plan, execute, and approve verification. QA approves the approach and the acceptance criteria for critical aspects, but the technical judgment sits with the experts.

Read as a whole, the standard points at a single outcome: the equipment and systems used to make the product should be genuinely suitable for the job the process asks of them. Getting there has three parts, and they run in order. The elements that matter to quality and to patient safety have to be designed properly in the first place. They then have to be shown, with evidence, to behave the way the design intended. And they have to be kept that way for as long as the system stays in service. Design it right, demonstrate it works, sustain it. That third part is what stops qualification from being a one-off ceremony at handover and turns it into something that has to hold up over years of operation.

That idea, fit for intended use, is the heart of it. You are not proving the equipment was installed exactly per a checklist. You are proving it does the job the process needs.

The vocabulary: commissioning, qualification, verification

This is where people get tangled, so be precise.

Commissioning is the engineering side of bringing a new facility, system, or piece of equipment from construction into working service and handing it over to the people who will run it. Done properly it is planned out in advance rather than improvised, recorded as it happens, and actively managed against a schedule and a punch list. What it should end with is a plant that is safe to operate, that does what the design said it would do, and that the people who asked for it are willing to accept. Commissioning sits under good engineering practice. On its own it is not a GMP activity, but the records it generates can feed straight into GMP verification when they have been kept to a high enough standard.

Qualification is the traditional GMP term for documented evidence that equipment is installed correctly, operates correctly, and performs correctly for its intended use. Regulations use this word. EU GMP Annex 15 uses IQ/OQ/PQ. The FDA process validation guidance uses “qualification” within Stage 2.

Verification is the term E2500 uses, and it is deliberately wider than qualification. It covers any organised, evidence-producing activity that establishes a manufacturing system does the job the process needs it to do, has been put in place correctly, and behaves correctly once running. That test applies to a single system examined on its own, and equally to several of them working together as an integrated whole, which matters because integration failures are one of the places site verification most often has to fill a gap. Verification is the umbrella. It can be satisfied by commissioning activities, by vendor testing, by qualification protocols, or by any documented engineering activity that provides the needed assurance, as long as the activity covers a critical aspect and meets predefined acceptance criteria with appropriate rigor and approval.

The key mental shift: E2500 does not delete IQ/OQ/PQ. It says the objective is verification of critical aspects, and IQ/OQ/PQ are some of the tools you can use to get there, not the only ones, and not mandatory in their classic form. Many sites keep the IQ/OQ/PQ deliverable names because regulators and their own quality systems expect them, but they execute them in a leaner, risk-targeted way and let commissioning carry the non-critical load.

The C&Q lifecycle, step by step

Here is the flow an E2500-aligned program follows, in sequence. Each step has a deliverable and a decision.

Step 1: User Requirements Specification (URS)

Everything starts here. The URS captures what the system must do, expressed in process and quality terms. It is the anchor for the entire lifecycle because critical aspects and acceptance criteria trace back to requirements.

What goes in it:

• Process requirements (capacity, throughput, materials of construction, temperature and pressure ranges, cycle requirements).
• Quality requirements derived from CQAs and CPPs (for a bioreactor: temperature control band, pH control, sterility boundary integrity, mixing).
• Regulatory and data integrity requirements (21 CFR Part 11 / EU Annex 11 for any computerized control, audit trail, access control).
• Safety, environmental, and operability requirements (these are real, but most are GEP, not GMP-critical).

Each requirement should be uniquely numbered and testable. A requirement you cannot verify is a requirement you should rewrite. See user-requirements-and-traceability for how to write requirements that survive a traceability audit.

Step 2: Risk assessments (the two that drive scope)

Two assessments shape an E2500 program. Do not confuse them.

System Impact Assessment. This older-style tool (from the first ISPE Baseline Guide) classifies whole systems as Direct Impact, Indirect Impact, or No Impact on product quality. Direct Impact systems get qualification effort. Indirect and No Impact systems get commissioning (GEP) only. The Second Edition Baseline Guide de-emphasizes system-level impact in favor of component-level criticality, but you will still see impact assessments in practice and in legacy procedures, so understand them.

Component Criticality Assessment / Critical Aspect identification. This is the engine of E2500. For each system, you decompose it into components or design functions and ask: does this aspect affect a CQA or a CPP, or does it create a direct risk to patient safety? If yes, it is critical and must be verified. If no, GEP commissioning is sufficient.

How to run the criticality assessment:

1. Start from the CQAs and CPPs established in process development and the control strategy (ICH Q8, Q11).
2. List the system’s components, instruments, and functions.
3. For each, ask whether it controls, monitors, or could compromise a CQA/CPP.
4. Assign a criticality call (Critical or Non-Critical), with documented rationale.
5. For critical aspects, define the verification activity and acceptance criteria.

A worked snippet for a jacketed bioreactor:

Notice that two functions on the same skid land in different buckets. That is the entire point: you are not qualifying “the bioreactor,” you are verifying the critical aspects of the bioreactor and commissioning the rest.

See quality-risk-management and equipment-qualification-lifecycle for the broader framing.

Step 3: Functional and Design Specifications, and design review

The URS flows down into Functional Specifications (what the system does to meet requirements) and Design Specifications (how it is built). For automated systems this includes the control philosophy, alarms, interlocks, and the computerized system layer governed by GAMP 5. See gamp5-csv-framework.

Design review is a formal, documented examination of the design against requirements, with SME and quality participation for critical aspects. E2500 leans heavily on design review and design qualification as the place where quality is built in. A good design review catches the missing alarm, the uncalibratable sensor, the dead leg, before steel is cut. That is far cheaper than catching it during verification.

Design Qualification (DQ), the documented verification that the proposed design is suitable, is still expected by Annex 15 and remains a clean fit inside the E2500 model: it is verification applied to the design.

Step 4: Verification planning

Before execution, the verification strategy is documented, usually in a Commissioning and Qualification Plan (sometimes folded into the Validation Master Plan or a project-specific C&Q plan). See validation-master-plan-and-periodic-review.

What the C&Q plan defines:

• Scope and system boundaries.
• The risk and criticality approach being used.
• What will be commissioned (GEP) vs verified (GMP).
• The reusing strategy: which vendor and commissioning activities will be used as qualification evidence, and the controls that make them acceptable.
• Acceptance criteria philosophy and deviation handling.
• Roles and approval matrix (who approves what).
• The deliverables list and how they trace.

Step 5: Execution (commissioning and verification testing)

This is where the leaner model shows up physically. In a classic program you would do Factory Acceptance Testing, Site Acceptance Testing, then a fresh IQ, then OQ. In an E2500 program you plan FAT/SAT so that their results, when properly witnessed and documented, become part of the verification record and are not re-executed at the site without reason.

See factory-site-acceptance-testing for FAT/SAT mechanics.

Execution sequence in practice:

1. FAT at the vendor: witness critical functions, capture documented results, raise punch-list items.
2. Installation and commissioning at the site: GEP checks (utilities connected, instruments installed, P&ID walkdown, loop checks).
3. SAT: confirm the system performs after shipping and installation; for critical aspects already verified at FAT, SAT may confirm rather than re-prove, with rationale.
4. Verification testing of critical aspects: the activities that prove fitness for intended use against acceptance criteria. These get full quality oversight.
5. Performance verification (the PQ equivalent): demonstrate the system performs reproducibly under loaded / process-representative conditions, often with placebo or process material.

A critical aspect can be verified once, by whichever activity is most appropriate, as long as the activity has the right rigor, predefined acceptance criteria, and proper approval. Industry practice describes this as reusing existing evidence, or building on work already done instead of repeating it, and whatever term your own procedures settle on, it is the single biggest source of cost and time savings in the model. The saving is real but conditional: it only materialises if the earlier record was disciplined enough to stand on its own as GMP evidence, which is why the quality of commissioning documentation ends up driving the economics of the whole programme.

Step 6: Acceptance and release / Acceptance and Release report

Once verification is complete, an Acceptance and Release decision is made and documented. The SME confirms critical aspects were verified against acceptance criteria; QA confirms the process was followed and the system is acceptable for GMP use. The summary report rolls up results, deviations and their resolution, and any open items, and states the conclusion that the system is fit for intended use. See validation-summary-report-and-release.

Step 7: Maintaining the state of control

E2500 explicitly covers the operational phase. After release, the system stays qualified through calibration, preventive maintenance, change control, and periodic review. Critical instruments go into the calibration-and-metrology-program. Changes go through change-control-validated-systems. Periodic review confirms the system is still fit for use. See requalification-and-periodic-review-equipment.

Reusing vendor documentation: where the money is, where the traps are

The promise of E2500 is that you stop re-testing what the vendor already tested correctly. The risk is that you accept vendor paper that does not actually establish anything. Getting this right is the skill that separates a strong C&Q engineer from a weak one.

What you can reuse

• FAT and SAT results for critical functions, when the test was witnessed, the acceptance criteria were predefined and quality-relevant, and the documentation is contemporaneous and complete.
• Vendor calibration certificates, when the standards used are traceable (NIST or equivalent national standard) and in date.
• Vendor material certifications (mill certs, certificates of conformance for materials of construction, surface finish records).
• Vendor weld documentation, passivation, and pressure test records for fluid systems.
• Software development and testing records from a competent supplier, assessed under GAMP 5 and a supplier assessment.

The conditions that make reusing defensible

Reusing is not “trust the vendor.” It is “verify the vendor is trustworthy, then verify the evidence is good.” You need:

1. A supplier assessment establishing the vendor has a quality system capable of producing reliable evidence. See supplier-vendor-qualification and software-supplier-assessment-csa.
2. Predefined acceptance criteria in the FAT/SAT protocol that map to critical aspects, approved before execution. Vendor test plans written purely for engineering signoff often do not test the GMP-critical attribute at all.
3. Documentation that meets data integrity expectations: attributable, legible, contemporaneous, original, accurate, and the four plus attributes, complete, consistent, enduring, available (ALCOA+). A FAT result recorded a week later from memory is not reusable. See ALCOA+ in detail.
4. Quality oversight proportionate to criticality: for critical aspects, quality reviews and approves the plan and the acceptance criteria, and witnesses or reviews the result.
5. A gap analysis: what did the vendor test cover, what did it not cover, and what site verification fills the gaps (for example, performance under your actual process load, or integration with site utilities and the site control system).

Worked example of a reusing decision

A chromatography skid arrives with a vendor FAT package. Decision logic:

None of the five critical aspects are reused outright: three are reused then confirmed at site or SAT (flow rate, UV detector, conductivity), and two require fresh site verification (DCS integration, which cannot be reused, and the cleaning cycle at process conditions). That table, documented with rationale, is exactly what an inspector wants to see, and it is exactly the documented science-based judgment E2500 is asking for.

A common and costly mistake is the all-or-nothing reflex: either re-execute everything at the site (wasteful, and the original argument for E2500) or wave through the entire vendor package (indefensible). The right answer is almost always per-aspect.

Good Engineering Practice: the foundation under everything

Good engineering practice is shorthand for doing the engineering properly: applying recognised methods, codes, and industry standards consistently from the earliest concept work through design, procurement, construction, and handover, so that what actually gets built is suitable for the duty it has to perform, sensibly specified, and delivered without spending money on capability the process will never use. It is a working discipline rather than a document set, and it applies to every system on a site whether or not that system touches product. In the E2500 model, GEP is not a lesser activity; it is the base layer that all qualified work sits on. Commissioning is GEP. The design process is GEP. Document management, vendor management, and change management during the project are GEP.

The practical consequence: GEP documentation has to be good enough that GMP verification can lean on it. If your commissioning records are sloppy, you cannot reuse them, and you lose the entire benefit of the approach. Sites that succeed with E2500 raise the quality of their engineering documentation so that the line between commissioning and qualification is about criticality, not about rigor. A commissioning record and a verification record should look equally disciplined; what differs is whether quality formally approves it and whether it covers a critical aspect.

How E2500 maps to the regulations that actually bind you

E2500 is voluntary. The regulations are not. You must show that your E2500 program satisfies them. Here is the crosswalk every practitioner should be able to recite.

FDA Process Validation Guidance (2011), “Process Validation: General Principles and Practices.” Stage 1 (Process Design), Stage 2 (Process Qualification), Stage 3 (Continued Process Verification). Equipment qualification lives inside Stage 2. The guidance is explicitly lifecycle and risk-based, which is why E2500 fits cleanly. Stage 3 is mirrored by E2500’s “maintain a state of control.” See process-validation-lifecycle and continued-process-verification-cpv.

EU GMP Annex 15, “Qualification and Validation” (current revised version effective 2015). This is the one that still names URS, DQ, IQ, OQ, PQ. Annex 15 explicitly allows a risk-based approach and explicitly permits reusing good documentation: it states that FAT/SAT and supplier documentation can be used to reduce duplicate testing where justified. So E2500-style reusing is not in tension with Annex 15; Annex 15 invites it. Your job is to keep the IQ/OQ/PQ verification objectives covered while changing how you meet them.

21 CFR 211.63 and 211.68. Equipment must be of appropriate design and adequate size, suitably located, and (for automated/electronic equipment) routinely calibrated, inspected, or checked. These are outcome requirements; E2500 is one way to demonstrate them. See cfr-210-211-cgmp-walkthrough.

ICH Q9 (Quality Risk Management) provides the risk methodology that E2500 assumes. ICH Q8 / Q11 provide the product and process understanding (CQAs, CPPs, control strategy) that defines what is critical. ICH Q10 provides the pharmaceutical quality system context. Together they are the science that makes the science-based approach more than a slogan.

The single most important thing to be able to say in front of an inspector: “We use ASTM E2500 as our methodology, but our deliverables demonstrate compliance with Annex 15 and the FDA process validation lifecycle. Every critical aspect traces to a CQA or CPP, was verified against predefined acceptance criteria, and was approved by an SME and Quality.”

Roles and responsibilities

E2500 changed who decides. The shift from QA-approves-everything to SME-leads-with-QA-oversight is the most misunderstood part of the standard, and the part inspectors probe.

The interview-grade nuance: under the older paradigm, QA was expected to review and approve essentially every qualification document. Under E2500, QA’s role on non-critical, GEP activities shrinks deliberately, and QA focuses its review where criticality is. A common failure mode is an organization that adopts E2500 language but never actually puts decision authority in SME hands or scales back QA review, so it gets all the documentation burden of the old way plus the unfamiliarity of the new way. See gxp-roles-responsibilities.

Acceptance criteria: what “good” looks like

Acceptance criteria in an E2500 program have to be sharper than in a tick-box IQ, because they carry the entire weight of proving fitness for use. Rules of thumb:

• Quantitative and tied to the process need. “Temperature controls to ±0.5 °C of setpoint across the operating range” beats “temperature controls adequately.” The number should come from the CPP / control strategy, not be invented at protocol-writing time.
• Predefined and approved before execution. Setting or relaxing acceptance criteria after seeing the result is one of the fastest ways to a data integrity finding.
• Mapped to a critical aspect. Every acceptance criterion for a verification activity should trace to a critical aspect, which traces to a CQA/CPP, which traces to a URS line. That traceability chain is your defense.
• Achievable with the installed measurement. If the acceptance criterion is ±0.5 °C and your installed sensor’s calibrated accuracy is ±0.6 °C, you cannot pass honestly. Criticality assessment should have caught this at design review.

A finished verification looks like this when it is done well:

• Criticality assessment approved, with rationale for each Critical / Non-Critical call.
• Traceability matrix linking URS, critical aspects, verification activities, and results.
• Verification protocols with predefined, quantitative acceptance criteria, executed contemporaneously, deviations raised and resolved.
• A clear reusing log: what was reused, from whom, why it was acceptable, and what gaps were closed at site.
• An Acceptance and Release report concluding fitness for intended use, SME and QA approved.

See validation-deliverables-guide and writing-validation-protocols-and-reports.

Common mistakes and inspection-finding patterns

These are the patterns that show up in deficiency observations and in failed programs. None of them name a company; they are generic.

1. “E2500 means we don’t have to qualify.” No. E2500 means you verify critical aspects with appropriate rigor. Treating it as permission to skip testing, with no documented criticality rationale, gets cited as inadequate qualification. The standard reduces effort on non-critical aspects, not on critical ones.

2. Criticality assessments that are not science-based. Calling something non-critical with no link to a CQA/CPP, or with a one-word rationale like “vendor,” is the most common substantive finding. The whole model rests on the criticality call, so a weak or undocumented assessment collapses the defense for everything downstream.

3. Reusing vendor documents that do not establish anything. Accepting a FAT package where the acceptance criteria were generic engineering signoffs, not GMP-critical limits, or where results were not contemporaneous, or where there was no supplier assessment. Inspectors pull the underlying vendor record and check whether it actually tested the critical attribute.

4. Acceptance criteria set or changed after execution. A data integrity problem wearing a C&Q costume. If criteria were not approved before execution, the verification is suspect. See data-integrity-foundations.

5. No traceability. The criticality assessment, the URS, the verification activities, and the results do not connect. An inspector asks “show me where this critical aspect was verified” and the team cannot trace it. See user-requirements-and-traceability.

6. Adopting the language but not the roles. SMEs are named on paper but QA still gatekeeps every document and SMEs do not actually approve verification. The program gets the overhead of two systems and the benefits of neither.

7. Sloppy commissioning that cannot be reused. Because GEP records were not kept to ALCOA+ standard, nothing can be reused, so site teams re-execute everything, and the cost savings evaporate. The fix is upstream: raise commissioning documentation quality.

8. Computerized systems treated as an afterthought. The control system, alarms, interlocks, audit trail, and access control are critical aspects for most automated equipment and need GAMP 5 / CSA treatment, not just a loop check. See computer-software-assurance-fda and automation-validation-plc-scada-dcs.

9. Forgetting the operational phase. A beautiful verification at handover, then no calibration program, no change control discipline, no periodic review. State of control is a requirement of the standard and of GMP, not an optional extra.

Interview questions and how to answer them

“What is ASTM E2500 and how is it different from traditional IQ/OQ/PQ?” E2500 is a consensus standard for the specification, design, and verification of manufacturing systems. The core difference is that it organizes effort around verifying critical aspects (functions that affect CQAs, CPPs, or patient safety) rather than executing a uniform IQ/OQ/PQ on everything. It introduces verification as the umbrella objective, allows reuse of commissioning and vendor documentation, and puts SMEs at the center of acceptance decisions. It does not abolish IQ/OQ/PQ; many sites keep those deliverable names but execute them leaner and risk-targeted.

“Is E2500 a regulatory requirement?” No. It is a voluntary ASTM consensus standard. It is recognized because its principles align with ICH Q8/Q9/Q10, the FDA process validation lifecycle guidance, and EU GMP Annex 15. You still have to demonstrate compliance with those binding requirements; E2500 is one accepted methodology for doing so.

“How do you decide what is critical?” Start from the product and process understanding: the CQAs and CPPs and the control strategy. Decompose the system into components and functions. For each, ask whether it controls, monitors, or could compromise a CQA or CPP, or creates a direct patient-safety risk. If yes, it is critical and must be verified against predefined acceptance criteria. If no, good engineering practice commissioning is sufficient. Document the rationale for every call.

“When can you reuse vendor or FAT documentation, and when can’t you?” You can reuse when there is a supplier assessment establishing the vendor’s quality system, the test had predefined GMP-relevant acceptance criteria, the documentation meets ALCOA+, quality oversight was proportionate to criticality, and a gap analysis confirms what site verification still has to cover. You cannot reuse when the vendor test did not cover the critical attribute, was not contemporaneous, used unsuitable acceptance criteria, or where the function only exists once integrated at the site (control system integration, performance under actual process load).

“How does E2500 relate to Annex 15?” Annex 15 still defines URS, DQ, IQ, OQ, PQ, but it explicitly allows a risk-based approach and explicitly permits using FAT/SAT and supplier documentation to avoid duplicate testing where justified. So an E2500 program and Annex 15 are compatible: E2500 is the methodology, and your deliverables show you met Annex 15’s verification objectives.

“Who approves verification under E2500?” The SME plans, executes, and approves verification of critical aspects within their expertise and defines acceptance criteria. QA approves the overall approach and the acceptance criteria for critical aspects, and approves the Acceptance and Release. QA deliberately does not approve every GEP commissioning document. This rebalancing toward SME judgment, with QA oversight focused on criticality, is the heart of the model.

“What is the difference between commissioning and qualification here?” Commissioning is the GEP engineering startup and turnover activity; by itself it is not a GMP activity. Qualification (verification, in E2500 terms) is documented GMP evidence that critical aspects are fit for intended use. The line between them is criticality, not rigor: good commissioning documentation should be disciplined enough to be reused as verification evidence.

“How do you keep a system qualified after release?” Through the operational phase controls the standard requires: calibration and preventive maintenance, change control on the validated state, and periodic review confirming continued fitness for use. This is the state-of-control requirement and it maps to Stage 3 of the FDA lifecycle.

Practical tips

• Build the traceability matrix early and keep it live. URS to critical aspect to verification activity to result. It is the spine of the whole program and the first thing a good inspector asks to walk.
• Write acceptance criteria from the control strategy, not from the protocol template. If you cannot point to where a limit came from, it is probably arbitrary.
• Spend disproportionate effort on design review and DQ. Every critical aspect problem caught here is one you do not have to catch (expensively) during verification or (catastrophically) in production.
• Treat the criticality assessment as the load-bearing document. Get it right, get it cross-functionally reviewed, and get the rationale written so a stranger can follow it.
• Make your commissioning documentation good enough to reuse. The savings come from reusing, and you can only reuse records that meet ALCOA+.
• For automated equipment, run the C&Q and the computerized system validation as one integrated effort, not two parallel ones, so the control system critical aspects are covered once and traced cleanly.
• Keep a clear reusing log so that, two years later in an inspection, anyone can see what you leaned on and why it was acceptable.

Related articles

• equipment-qualification-lifecycle
• factory-site-acceptance-testing
• validation-deliverables-guide
• user-requirements-and-traceability
• quality-risk-management
• process-validation-lifecycle
• requalification-and-periodic-review-equipment
• gamp5-csv-framework
• equipment-qualification-audit-checklist
• validation-master-plan-and-periodic-review